Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026

Arvinas (ARVN) will review third quarter 2026 financial results and provide a corporate update during a webcast on November 3, 2026.

Rhea-AI Summary

Arvinas (ARVN) will review third quarter 2026 financial results and provide a corporate update during a webcast on November 3, 2026. The live webcast begins at 8:00 a.m. ET and will be accessible through “Events and Presentations” on the company’s investor page. A replay will be available on the Arvinas website after the event.

Key Figures

Webcast timing: November 3, 2026, 8:00 a.m. ET

Webcast timing

November 3, 2026, 8:00 a.m. ET

Scheduled review of third-quarter 2026 financial results and corporate update

Key Terms

protac, heterobifunctional protein degrader

2 terms

protac technical

"Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform"

A PROTAC (proteolysis targeting chimera) is a small engineered molecule that tags a specific protein inside cells and brings it to the cell’s disposal machinery so the protein is destroyed rather than just blocked. Think of it as a targeted cleanup crew that removes a problematic part instead of temporarily turning it off. Investors care because PROTACs can tackle disease targets that traditional drugs cannot, creating potential for breakthrough therapies, larger markets, and binary clinical readouts that can sharply affect company value.

heterobifunctional protein degrader technical

"a type of heterobifunctional protein degrader"

A heterobifunctional protein degrader is a designed molecule with two linked ends: one binds a specific target protein and the other recruits the cell’s protein-removal machinery, forcing the cell to tag and destroy the target. Think of it as a molecular bridge that brings a marked item to the cell’s trash system. It matters to investors because it represents a therapeutic approach that can remove disease-related proteins and can expand drug pipelines and valuation prospects for biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET.

The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.

About Arvina

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization. 

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. 

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com